Impact of once-daily extended-release quetiapine fumarate on hospitalization length in patients with acute bipolar mania. (January 2015)

• Record Type: Journal Article
• Authors: Bonafede, Machaon; Locklear, Julie C; Wahlqvist, Peter; Fajutrao, Liberty; Szamosi, Johan; Pan, Katy; Eriksson, Hans
• Is Part Of: Journal of comparative effectiveness research. Volume 4:Number 1(2015)
• Page Start: 51
• Page End: 59
• Publication Date: 2015-01
• Subjects: acute bipolar mania -- cost -- hospitalization -- quetiapine XR; Medical care -- Research -- Periodicals; Medical care -- Research -- Evaluation -- Periodicals; Medical care -- Decision making -- Periodicals; Evidence-based medicine -- Periodicals; Medicine, Comparative -- Periodicals; 362.1072
• DOI: 10.2217/cer.14.48
• Languages: English
• ISSNs: 2042-6305

Abstract

Aims: Evaluate the impact of quetiapine extended release (XR) versus quetiapine immediate release (IR) on hospitalization length in acute bipolar mania using Truven Health Analytics MarketScan ® Hospital Drug Database.Patients & methods: Generalized linear model analyses were used, adjusting for patient and hospital characteristics.Results: Using data from 3088 discharges, quetiapine XR reduced hospitalization length by 6.7% versus quetiapine IR (p = 0.11; no statistically significant differences between groups), corresponding to 0.6 fewer days in hospital. Excluding the outlier, quetiapine XR significantly reduced hospitalization length by 9.6% versus quetiapine IR (p = 0.02), corresponding to 0.9 days.Conclusion: Inpatient use of quetiapine XR in acute bipolar mania may be associated with reduced hospitalization length (7–10%), possibly owing to the faster titration schedule versus quetiapine IR.